GlassScriptPhysician profile
Humberto Dorta
NPI 1629044128
$8,233.41
in general payments reported to CMS, 2019-2025
25 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $788 · 2021: $1,311 · 2022: $1,203 · 2023: $1,288 · 2024: $1,206 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846 · Education: $91.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.47 |
| Education | $91.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $931.28 | 2020-2025 | Caplyta |
| Alkermes, INC. | $894.56 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $803.71 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $803.36 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $676.83 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $665.64 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $645.21 | 2019-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $612.27 | 2022-2025 | Auvelity |
| Abbvie INC. | $385.64 | 2021-2023 | Vraylar |
| Indivior INC. | $322.92 | 2019-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $314.96 | 2019-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $243.04 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $203.13 | 2019-2022 | |
| Novo Nordisk INC | $130.69 | 2022-2025 | Wegovy, Saxenda |
| Avanir Pharmaceuticals, INC. | $129.15 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $114.64 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.95 | 2025 | Cobenfy |
| Allergan, INC. | $63.19 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $48.98 | 2019-2020 | |
| Lilly USA, LLC | $40.58 | 2025 | Zepbound |
| Ironshore Pharmaceuticals INC. | $34.94 | 2019 | |
| Sage Therapeutics, LLC | $26.21 | 2025 | Zurzuvae |
| Corium, LLC | $21.05 | 2025 | Azstarys |
| Neuronetics, INC. | $16.33 | 2022 | |
| Orexo US, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humberto Dorta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.